Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.

BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

Saudi Arabia is emerging as a major growth market for clinical trials in the Middle East, underpinned by strong funding and rapidly developing infrastructure.

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).